Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Goldman Sachs Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $31
Goldman Sachs analyst Chris Shibutani maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 44.9% and a
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Consumer price index data this week provided encouraging signs that American inflation is moving ever closer to the Federal Reserve's much-discussed 2% target.This fueled speculation about interest
Pfizer Options Spot-On: On July 12th, 180.09K Contracts Were Traded, With 2.9 Million Open Interest
On July 12th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 180.09K options for the day, of which put options accounted for 33.57% of the total transactions, and
Unusual Options Activity: RDDT, GXO and Others Attract Market Bets, RDDT V/OI Ratio Reaches 200.2
EST Jul 12th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
What the 2000's Tech Bubble Says About Today's Suspected Rotation - Analyst
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Thursday, Pfizer Inc (NYSE:PFE) announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.Pfizer plans to
PFE or NVO: Which Is the Better Value Stock Right Now?
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
UBS Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $30
UBS analyst Trung Huynh maintains $Pfizer(PFE.US)$ with a hold rating, and adjusts the target price from $28 to $30.According to TipRanks data, the analyst has a success rate of 75.5% and a total
Novo's Ozempic Linked to Improved Brain Health: Study
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Pfizer(PFE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 51.5% and a total average return of 4.6% over
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE:PFE) as his final trade on the latest edition of CNBC's "Halftime Report Final Trades." On Thursday, Pfizer announced it will
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $29 to $35
On Jul 12, major Wall Street analysts update their ratings for $Pfizer(PFE.US)$, with price targets ranging from $29 to $35.Morgan Stanley analyst Terence Flynn maintains with a hold rating, and
Daily short sale tracking: NVIDIA's short volume increased by 22 million, with a short sale ratio of 10%
NVIDIA(NVDA.US) ranked top of the list had the largest change in short volume (22.53 million shares), and the short volume ratio of Western Midstream(WES.US) reached 38.14%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Express News | Pfizer Inc : UBS Raises Target Price to $30 From $28
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)